The Huntsman Cancer Institute at the University of Utah (HCI) is a wellspring of expertise for patients with benign hematologic disorders living in the Mountain West, the largest geographic catchment area in the United States. Our mission is to deliver coordinated, multispecialty care, as a medical home, for patients with non-malignant hematologic disorders, including patients with hemophilia and other inherited or acquired bleeding and thrombotic disorders; patients with acquired bone marrow failure disorders, such as aplastic anemia and paroxysmal nocturnal hemoglobinuria; patients with abnormalities of heme, globin and iron metabolism, including porphyria, hemoglobinopathies, thalassemia and hemochromatosis; patients with both immune and non-immune hemolytic anemia, immune thrombocytopenic purpura, immune neutropenia; and patients with polycythemia, thrombocytosis and leukocytosis.
Our faculty members consult on the inpatient service at the University of Utah and the Huntsman Cancer Hospital for both primary hematologic disorders, such as acute thrombotic thrombocytopenic purpura and complications of sickle cell disease, and secondary hematologic manifestations of medical and surgical disorders such as anemia, heparin induced thrombocytopenia and anti-phospholipid syndrome.
In addition to supporting the medical, surgical and obstetrics and gynecology services, the benign hematology team compliments the multidisciplinary approach to the cancer wellness center, with transfusion medicine support, prevention and treatment of both cancer associated deep venous thrombosis, and cytopenias secondary to cancer chemotherapy.
